36 results on '"Brian J. Long"'
Search Results
2. Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
- Author
-
George H. Addona, David Jonathan Bennett, Brian J. Long, Sheila Ranganath, Anuradha Khilnani, Archie Tse, B. Wesley Trotter, Jared Cumming, Saso Cemerski, Ian Knemeyer, Vincenzo Pucci, Hyun Chong Woo, Sharad K. Sharma, Shuxia Zhao, Bo-Sheng Pan, Jennifer Piesvaux, Heidi M. Ferguson, Ellen C. Minnihan, Sarah Javaid, Manjiri Sathe, Jeremy Presland, Long Cui, Yiping Chen, Kalyan Chakravarthy, Jason Laskey, Eric S. Muise, Yanhong Ma, Johnny E. Kopinja, and Samanthi A. Perera
- Abstract
Supplementary Methods and Figures
- Published
- 2023
3. Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
- Author
-
Elaine M. Pinheiro, Terrill K. McClanahan, Brian J. Long, Svetlana Sadekova, Razvan Cristescu, Andrey Loboda, Derek Y. Chiang, Lily Y. Moy, Aleksandra K. Olow, Sarah Javaid, Heather A. Hirsch, Kimberly S. Kerr, Wendy M. Blumenschein, Manjiri Sathe, Michael Nebozhyn, Venkataraman Sriram, Jennifer H. Yearley, Hui Xiao, Lan Chen, Michael Caniga, Selvakumar Sukumar, Douglas C. Wilson, Louise Cadzow, Mingmei Cai, Yun Wang, Marlene C. Hinton, Douglas E. Linn, Eric S. Muise, and Peter Georgiev
- Abstract
Targeting the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway with immunotherapy has revolutionized the treatment of many cancers. Somatic tumor mutational burden (TMB) and T-cell–inflamed gene expression profile (GEP) are clinically validated pan-tumor genomic biomarkers that can predict responsiveness to anti-PD-1/PD-L1 monotherapy in many tumor types. We analyzed the association between these biomarkers and the efficacy of PD-1 inhibitor in 11 commonly used preclinical syngeneic tumor mouse models using murinized rat anti-mouse PD-1 DX400 antibody muDX400, a surrogate for pembrolizumab. Response to muDX400 treatment was broadly classified into three categories: highly responsive, partially responsive, and intrinsically resistant to therapy. Molecular and cellular profiling validated differences in immune cell infiltration and activation in the tumor microenvironment of muDX400-responsive tumors. Baseline and on-treatment genomic analysis showed an association between TMB, murine T-cell–inflamed gene expression profile (murine-GEP), and response to muDX400 treatment. We extended our analysis to investigate a canonical set of cancer and immune biology-related gene signatures, including signatures of angiogenesis, myeloid-derived suppressor cells, and stromal/epithelial-to-mesenchymal transition/TGFβ biology previously shown to be inversely associated with the clinical efficacy of immune checkpoint blockade. Finally, we evaluated the association between murine-GEP and preclinical efficacy with standard-of-care chemotherapy or antiangiogenic agents that previously demonstrated promising clinical activity, in combination with muDX400. Our profiling studies begin to elucidate the underlying biological mechanisms of response and resistance to PD-1/PD-L1 blockade represented by these models, thereby providing insight into which models are most appropriate for the evaluation of orthogonal combination strategies.
- Published
- 2023
4. Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
- Author
-
Elaine M. Pinheiro, Terrill K. McClanahan, Brian J. Long, Svetlana Sadekova, Razvan Cristescu, Andrey Loboda, Derek Y. Chiang, Lily Y. Moy, Aleksandra K. Olow, Sarah Javaid, Heather A. Hirsch, Kimberly S. Kerr, Wendy M. Blumenschein, Manjiri Sathe, Michael Nebozhyn, Venkataraman Sriram, Jennifer H. Yearley, Hui Xiao, Lan Chen, Michael Caniga, Selvakumar Sukumar, Douglas C. Wilson, Louise Cadzow, Mingmei Cai, Yun Wang, Marlene C. Hinton, Douglas E. Linn, Eric S. Muise, and Peter Georgiev
- Abstract
Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
- Published
- 2023
5. Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
- Author
-
George H. Addona, David Jonathan Bennett, Brian J. Long, Sheila Ranganath, Anuradha Khilnani, Archie Tse, B. Wesley Trotter, Jared Cumming, Saso Cemerski, Ian Knemeyer, Vincenzo Pucci, Hyun Chong Woo, Sharad K. Sharma, Shuxia Zhao, Bo-Sheng Pan, Jennifer Piesvaux, Heidi M. Ferguson, Ellen C. Minnihan, Sarah Javaid, Manjiri Sathe, Jeremy Presland, Long Cui, Yiping Chen, Kalyan Chakravarthy, Jason Laskey, Eric S. Muise, Yanhong Ma, Johnny E. Kopinja, and Samanthi A. Perera
- Abstract
Supplemental Table 1: Log2Ratio and p values for all 310 genes shown in Figure 6
- Published
- 2023
6. Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
- Author
-
Peter Georgiev, Eric S. Muise, Douglas E. Linn, Marlene C. Hinton, Yun Wang, Mingmei Cai, Louise Cadzow, Douglas C. Wilson, Selvakumar Sukumar, Michael Caniga, Lan Chen, Hui Xiao, Jennifer H. Yearley, Venkataraman Sriram, Michael Nebozhyn, Manjiri Sathe, Wendy M. Blumenschein, Kimberly S. Kerr, Heather A. Hirsch, Sarah Javaid, Aleksandra K. Olow, Lily Y. Moy, Derek Y. Chiang, Andrey Loboda, Razvan Cristescu, Svetlana Sadekova, Brian J. Long, Terrill K. McClanahan, and Elaine M. Pinheiro
- Subjects
Cancer Research ,Programmed Cell Death 1 Receptor ,B7-H1 Antigen ,Disease Models, Animal ,Mice ,Oncology ,Cell Line, Tumor ,Neoplasms ,Biomarkers, Tumor ,Tumor Microenvironment ,Animals ,Humans ,Immunotherapy ,Immune Checkpoint Inhibitors - Abstract
Targeting the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway with immunotherapy has revolutionized the treatment of many cancers. Somatic tumor mutational burden (TMB) and T-cell–inflamed gene expression profile (GEP) are clinically validated pan-tumor genomic biomarkers that can predict responsiveness to anti-PD-1/PD-L1 monotherapy in many tumor types. We analyzed the association between these biomarkers and the efficacy of PD-1 inhibitor in 11 commonly used preclinical syngeneic tumor mouse models using murinized rat anti-mouse PD-1 DX400 antibody muDX400, a surrogate for pembrolizumab. Response to muDX400 treatment was broadly classified into three categories: highly responsive, partially responsive, and intrinsically resistant to therapy. Molecular and cellular profiling validated differences in immune cell infiltration and activation in the tumor microenvironment of muDX400-responsive tumors. Baseline and on-treatment genomic analysis showed an association between TMB, murine T-cell–inflamed gene expression profile (murine-GEP), and response to muDX400 treatment. We extended our analysis to investigate a canonical set of cancer and immune biology-related gene signatures, including signatures of angiogenesis, myeloid-derived suppressor cells, and stromal/epithelial-to-mesenchymal transition/TGFβ biology previously shown to be inversely associated with the clinical efficacy of immune checkpoint blockade. Finally, we evaluated the association between murine-GEP and preclinical efficacy with standard-of-care chemotherapy or antiangiogenic agents that previously demonstrated promising clinical activity, in combination with muDX400. Our profiling studies begin to elucidate the underlying biological mechanisms of response and resistance to PD-1/PD-L1 blockade represented by these models, thereby providing insight into which models are most appropriate for the evaluation of orthogonal combination strategies.
- Published
- 2022
7. Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer
- Author
-
Wonsuk Chang, Michael D. Altman, Charles A. Lesburg, Samanthi A. Perera, Jennifer A. Piesvaux, Gottfried K. Schroeder, Daniel F. Wyss, Saso Cemerski, Yiping Chen, Edward DiNunzio, Andrew M. Haidle, Thu Ho, Ilona Kariv, Ian Knemeyer, Johnny E. Kopinja, Brian M. Lacey, Jason Laskey, Jongwon Lim, Brian J. Long, Yanhong Ma, Matthew L. Maddess, Bo-Sheng Pan, Jeremy P. Presland, Edward Spooner, Dietrich Steinhuebel, Quang Truong, Zhibo Zhang, Jianmin Fu, George H. Addona, Alan B. Northrup, Emma Parmee, James R. Tata, David Jonathan Bennett, Jared N. Cumming, Tony Siu, and B. Wesley Trotter
- Subjects
Mice ,Neoplasms ,Drug Discovery ,Molecular Medicine ,Animals ,Cytokines ,Humans ,Membrane Proteins ,Immunotherapy ,Interferons - Abstract
Stereochemically and structurally complex cyclic dinucleotide-based stimulator of interferon genes (STING) agonists were designed and synthesized to access a previously unexplored chemical space. The assessment of biochemical affinity and cellular potency, along with computational, structural, and biophysical characterization, was applied to influence the design and optimization of novel STING agonists, resulting in the discovery of MK-1454 as a molecule with appropriate properties for clinical development. When administered intratumorally to immune-competent mice-bearing syngeneic tumors, MK-1454 exhibited robust tumor cytokine upregulation and effective antitumor activity. Tumor shrinkage in mouse models that are intrinsically resistant to single-agent therapy was further enhanced when treating the animals with MK-1454 in combination with a fully murinized antimouse PD-1 antibody, mDX400. These data support the development of STING agonists in combination with pembrolizumab (humanized anti-PD-1 antibody) for patients with tumors that are partially responsive or nonresponsive to single-agent anti-PD-1 therapy.
- Published
- 2022
8. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
- Author
-
Robert N Booher, Harold Hatch, Brian M Dolinski, Thi Nguyen, Lauren Harmonay, Ali-Samer Al-Assaad, Mark Ayers, Michael Nebozhyn, Andrey Loboda, Heather A Hirsch, Theresa Zhang, Bin Shi, Carrie E Merkel, Minilik H Angagaw, Yaolin Wang, Brian J Long, Xianlu Q Lennon, Nathan Miselis, Vincenzo Pucci, James W Monahan, Junghoon Lee, Anna Georgieva Kondic, Eun Kyung Im, David Mauro, Rebecca Blanchard, Gary Gilliland, Stephen E Fawell, Leigh Zawel, Alwin G Schuller, and Peter Strack
- Subjects
Medicine ,Science - Abstract
Dinaciclib is a potent CDK1, 2, 5 and 9 inhibitor being developed for the treatment of cancer. Additional understanding of antitumor mechanisms and identification of predictive biomarkers are important for its clinical development. Here we demonstrate that while dinaciclib can effectively block cell cycle progression, in vitro and in vivo studies, coupled with mouse and human pharmacokinetics, support a model whereby induction of apoptosis is a main mechanism of dinaciclib's antitumor effect and relevant to the clinical duration of exposure. This was further underscored by kinetics of dinaciclib-induced downregulation of the antiapoptotic BCL2 family member MCL1 and correlation of sensitivity with the MCL1-to-BCL-xL mRNA ratio or MCL1 amplification in solid tumor models in vitro and in vivo. This MCL1-dependent apoptotic mechanism was additionally supported by synergy with the BCL2, BCL-xL and BCL-w inhibitor navitoclax (ABT-263). These results provide the rationale for investigating MCL1 and BCL-xL as predictive biomarkers for dinaciclib antitumor response and testing combinations with BCL2 family member inhibitors.
- Published
- 2014
- Full Text
- View/download PDF
9. Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor Letrozole
- Author
-
Brian J. Long, Angela Brodie, Olga Goloubeva, Luciana Macedo, Gauri Sabnis, and Danijela Jelovac
- Subjects
MAPK/ERK pathway ,Cancer Research ,medicine.medical_specialty ,MAP Kinase Signaling System ,medicine.drug_class ,Mice, Nude ,Estrogen receptor ,Breast Neoplasms ,Biology ,Drug Administration Schedule ,Mice ,Growth factor receptor binding ,Cell Line, Tumor ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Nitriles ,medicine ,Animals ,Humans ,Protein kinase A ,Mice, Inbred BALB C ,Aromatase inhibitor ,Fulvestrant ,Aromatase Inhibitors ,Letrozole ,Estrogen Receptor alpha ,Triazoles ,Xenograft Model Antitumor Assays ,Enzyme Activation ,Tamoxifen ,Endocrinology ,Oncology ,Cancer cell ,Female ,Mitogen-Activated Protein Kinases ,medicine.drug - Abstract
Ovariectomized mice bearing tumor xenografts grown from aromatase-transfected estrogen receptor (ER)–positive human breast cancer cells (MCF-7Ca) were injected s.c. with 10 μg/d letrozole for up to 56 weeks. Western blot analysis of the tumors revealed that ERs (ERα) were increased at 4 weeks but decreased at weeks 28 and 56. Expression of erbB-2 and p-Shc increased throughout treatment, whereas growth factor receptor binding protein 2 (Grb2) increased only in tumors proliferating on letrozole (weeks 28 and 56). In cells isolated from tumors after 56 weeks and maintained as a cell line (LTLT-Ca) in 1 μmol/L letrozole, ERα was also decreased whereas erbB-2, adapter proteins (p-Shc and Grb2), and the signaling proteins in the mitogen-activated protein kinase (MAPK) cascade were increased compared with MCF-7Ca cells. Growth was inhibited in LTLT-Ca cells but not in MCF-7Ca cells treated with MAPK kinase 1/2 inhibitors U0126, and PD98059 (IC50 ∼25 μmol/L). PD98059 (5 μmol/L) also reduced MAPK activity and increased ERα to the levels in MCF-7Ca cells. Epidermal growth factor receptor kinase inhibitor, gefitinib (ZD1839) inhibited growth of LTLT-Ca cells (IC50 ∼10 μmol/L) and restored their sensitivity to tamoxifen and anastrozole. In xenografts, combined treatment with ER down-regulator fulvestrant and letrozole, prevented increases in erbB-2 and activation of MAPK and was highly effective in inhibiting tumor growth throughout 29 weeks of treatment. These results indicate that blocking both ER- and growth factor–mediated transcription resulted in the most effective inhibition of growth of ER-positive breast cancer cells.
- Published
- 2005
10. Model systems: Mechanisms involved in the loss of sensitivity to letrozole
- Author
-
Angela Brodie, Brian J. Long, Danijela Jelovac, Luciana Macedo, Olga Goloubeva, and Gauri Sabnis
- Subjects
Src Homology 2 Domain-Containing, Transforming Protein 1 ,MAP Kinase Signaling System ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Estrogen receptor ,Anastrozole ,Antineoplastic Agents ,Breast Neoplasms ,Pharmacology ,Models, Biological ,Biochemistry ,Mice ,Endocrinology ,Nitriles ,Tumor Cells, Cultured ,medicine ,Animals ,Humans ,Aromatase ,Fulvestrant ,Molecular Biology ,Adaptor Proteins, Signal Transducing ,GRB2 Adaptor Protein ,Mice, Inbred BALB C ,Aromatase inhibitor ,Estradiol ,biology ,Aromatase Inhibitors ,business.industry ,Letrozole ,Cell Biology ,Triazoles ,Antiestrogen ,Xenograft Model Antitumor Assays ,Tamoxifen ,Receptors, Estrogen ,Shc Signaling Adaptor Proteins ,Drug Resistance, Neoplasm ,biology.protein ,Cancer research ,Molecular Medicine ,Female ,business ,Signal Transduction ,medicine.drug - Abstract
A number of models have been used to study the development and treatment of breast cancer. Since most breast cancer patients are postmenopausal and treated with hormone therapy, we developed a model to simulate this type of patient. Tumors of human estrogen receptor (ER)—positive breast cancer cells transfected with aromatase (MCF-7Ca) are grown in immune suppressed mice. In this model, we have explored a number of strategies to optimize the antitumor efficacy of treatment such as combining the non-steroidal aromatase inhibitor letrozole with the antiestrogens, tamoxifen. This combination resulted in tumor suppression similar to the antiestrogen alone, but was less effective than letrozole alone. Clinical findings with the non-steroidal inhibitor anastrozole in combination with tamoxifen (ATAC trial) were consistent with our results. Although letrozole was the most effective single agent tested in the model, tumors ultimately began to grow during continued treatment. To investigate the mechanisms by which tumors adapt to growth during letrozole treatment, we determined the expression of signaling proteins in tumors during the course of letrozole treatment compared to the tumors of control mice. We found that tumors initially up regulated the ER, but subsequently receptor levels decreased in tumors unresponsive to letrozole. Adapter proteins (p-Shc and Grb-2) as well as all of the signaling proteins in the MAPK cascade (p-Raf, p-Mek1/2, and p-MAPK), but not Akt, were increased in tumors no longer responsive to letrozole. The results suggest that tumor cells adapt to estrogen deprivation during letrozole treatment by activation of alternate signaling pathways to increase transcription. When letrozole was combined with the pure antiestrogen fulvestrant, to down regulate ER, the combination was more effective than either letrozole or fulvestrant alone. Tumors regressed by 45% and were maintained without growth for the duration of the experiment (29 weeks). Down regulation of ER by fulvestrant may prevent cross talk between these signaling pathways. The results suggest that achieving more complete estrogen blockade may delay development of hormone-independent signaling pathways regulating proliferation.
- Published
- 2005
11. Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model
- Author
-
Nicol Macpherson, Danijela Jelovac, Olga Goloubeva, Brian J. Long, Apinya Thiantanawat, Venkatesh D. Handratta, Joseph Ragaz, and Angela Brodie
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Neoplasms, Hormone-Dependent ,medicine.drug_class ,Ovariectomy ,Transplantation, Heterologous ,Mice, Nude ,Anastrozole ,Breast Neoplasms ,Pharmacology ,Drug Administration Schedule ,Mice ,Breast cancer ,Estrogen Receptor Modulators ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Nitriles ,medicine ,Animals ,Humans ,Enzyme Inhibitors ,Aromatase ,skin and connective tissue diseases ,Mice, Inbred BALB C ,Aromatase inhibitor ,biology ,Fulvestrant ,Aromatase Inhibitors ,business.industry ,Letrozole ,Uterus ,Organ Size ,Triazoles ,Antiestrogen ,medicine.disease ,Disease Models, Animal ,Tamoxifen ,Disease Progression ,Linear Models ,biology.protein ,Female ,business ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
Background: The antiestrogen tamoxifen has potent activity against estrogen receptor–positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability. To determine the optimal way to use letrozole and tamoxifen, we studied their effects on a breast tumor xenograft model, MCF-7Ca, that is responsive to both antiestrogens and aromatase inhibitors. Methods: Female ovariectomized BALB/c athymic nude mice carrying xenograft tumors were treated daily subcutaneously with one of the following fi rst-line therapies for varying durations: no drug (control), tamoxifen (100 g/day) alone, letrozole (10 g/ day) alone, both drugs at the same time, or alternating 4-week courses of each drug (beginning with a course of tamoxifen or beginning with a course of letrozole). Tumor volumes and weights were estimated using linear mixedeffects models. The time to tumor doubling was calculated, and tumor weights in the treatment groups were compared, with adjustments for multiple comparisons being made with either Tukey’s or Dunnett’s procedure. Second-line therapies (with tamoxifen, letrozole, or fulvestrant) were initiated when tumors doubled in size under fi rst-line therapies. All statistical tests were two-sided. Results: The times for doubling of tumor volume were as follows: control, 3– 4 weeks; tamoxifen alone, 16 weeks; tamoxifen alternating with letrozole, 17–18 weeks; tamoxifen plus letrozole, 18 weeks; letrozole alternating with tamoxifen, 22 weeks; letrozole alone, 34 weeks. First-line treatment with letrozole was superior to treatment with tamoxifen alone or with the two drugs combined (at week 16, both P
- Published
- 2004
12. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor
- Author
-
Vincent C. O. Njar, Dmitry N. Grigoryev, Brian J. Long, and Angela H. Brodie
- Subjects
Male ,medicine.medical_specialty ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Transplantation, Heterologous ,Clinical Biochemistry ,Estrogen receptor ,Mice, SCID ,Biology ,Transfection ,urologic and male genital diseases ,Binding, Competitive ,Biochemistry ,Dexamethasone ,Cell Line ,Mice ,chemistry.chemical_compound ,Endocrinology ,Internal medicine ,LNCaP ,Tumor Cells, Cultured ,medicine ,Animals ,Humans ,Receptor ,Molecular Biology ,Prostatic Neoplasms ,Dihydrotestosterone ,Cell Biology ,Androgen ,Androgen receptor ,Gene Expression Regulation ,chemistry ,Receptors, Androgen ,Pregnenolone ,Mutation ,Molecular Medicine ,Steroids ,Growth inhibition ,Cell Division ,Neoplasm Transplantation ,medicine.drug - Abstract
Pregnenolone (P(5)), a common precursor of many steroids, is present in the blood of normal adult men at concentrations of 1-3 nM. In vitro, P(5) was found to stimulate LNCaP-cell proliferation 7-8-fold at a physiological concentration (2 nM), and 3-4-fold at a subphysiological concentration (0.2 nM). Growth stimulation at the 2-nM concentration was comparable with that of the androgen, dihydrotestosterone at its physiological concentration (0.5 nM; 9-10-fold increase in cell number). To determine whether P(5) or its metabolites were mediating this growth response, LNCaP cells were incubated with [3H]P(5) and high-performance liquid chromatography (HPLC) was performed. After a 48-h exposure, two unidentified metabolites were detected. Although, the P(5) metabolites slightly increased LNCaP-cell growth in vitro, their effect was significantly less than P(5) alone, suggesting that the growth stimulation was mediated by P(5) itself. We further showed that P(5) sustained its proliferative activity in vivo and stimulated the growth of LNCaP-tumor xenografts in intact male SCID mice as well as in castrated animals. In order to determine whether P(5) was binding to a specific site in LNCaP cells, receptor binding studies were performed. Scatchard analysis predicted for a single class of binding sites with K(d)=1.4 nM. Studies were performed to determine the effects of P(5) on transcription mediated by wild-type and LNCaP androgen receptors. P(5) was shown to activate transcription through the LNCaP androgen receptor (AR), but not the wild-type AR. This implies that P(5) most likely stimulates LNCaP-cell proliferation through binding to the cellular mutated AR present in LNCaP cells. We have also demonstrated that drugs designed to be antagonists of the androgen, progesterone and estrogen receptors, and one of our novel compounds designed to be an inhibitor of androgen synthesis, were potent inhibitors of the AR-mediated transcriptional activity induced by P(5), and were able to inhibit LNCaP-cell proliferation. These findings suggest that some prostate cancer patients who appear to become hormone-independent may have tumors which are stimulated by P(5) via a mutated AR and that these patients could benefit from treatment with antiestrogens, antiprogestins, or with some of our novel androgen synthesis inhibitors.
- Published
- 2000
13. Anti-tumour effects and pharmacokinetic profile of 17-(5′-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis
- Author
-
Dmitry N. Grigoryev, Nnane Ip, Brian J. Long, Angela Brodie, and Ling Yz
- Subjects
Male ,Cancer Research ,Prostatic Hyperplasia ,Flutamide ,Mice ,Prostate cancer ,chemistry.chemical_compound ,5-alpha Reductase Inhibitors ,Prostate ,Testis ,Tumor Cells, Cultured ,Enzyme Inhibitors ,Chromatography, High Pressure Liquid ,Steroid 17-alpha-Hydroxylase ,Regular Article ,prostate cancer ,Neoplasm Proteins ,17α-hydroxylase/C 17,20-lyase ,medicine.anatomical_structure ,Oncology ,Injections, Intravenous ,5α-reductase ,pharmacokinetics ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,medicine.drug_class ,Injections, Subcutaneous ,Transplantation, Heterologous ,Mice, Nude ,5 Alpha-Reductase Inhibitor ,Microsomes ,Internal medicine ,LNCaP ,medicine ,Animals ,Humans ,business.industry ,androgens ,Prostatic Neoplasms ,Cancer ,Androgen Antagonists ,medicine.disease ,Androgen ,Androstadienes ,Androgen receptor ,Endocrinology ,chemistry ,Drug Screening Assays, Antitumor ,business ,Neoplasm Transplantation - Abstract
17-(5′-Isoxazolyl)androsta-4,16-dien-3-one (L-39), a novel androstene derivative, was synthesized and evaluated in vitro and in vivo. L-39 showed potent and non-competitive inhibition of human testicular microsomal 17α-hydroxylase/C 17,20-lyase with an IC 50 value of 59 n M and Ki of 22 n M. L-39 also showed potent and competitive inhibition of 5α-reductase in human prostatic microsomes with IC 50 and Ki values of 33 and 28 n M respectively. L-39 (5 μM) has also been shown to manifest anti-androgenic activity in cultures of human prostate cancer cell lines (LNCaP) by preventing the labelled synthetic androgen R1881 (5 n M) from binding to the androgen receptors. Androgen-ependent human próstate cancer xenografts (PC-82) were grown in nude mice and the effects of L-39 (50 mg kg–1day–1) on tumour growth and prostate-specific antigen (PSA) levels were determined after 28 days. L-39 significantly (P< 0.01) diminished tumour growth and wet weights to a similar extent as castration or flutamide treatment. L-39 also significantly (P< 0.01) reduced serum PSA levels by more than 80% in the mice bearing human prostate cancer xenografts. Pharmacokinetic studies were also conducted in male Balb/c mice. After subcutaneous administration of a single bolus dose, L-39 was rapidly absorbed into the systemic circulation. Peak plasma levels occurred at 0.75 h and then declined with a t1/2 of 1.51 h. The bioavailability of L-39 after subcutaneous administration was 28.5%. These results demonstrate that L-39 is a potent inhibitor of androgen synthesis and is effective in reducing the growth of human prostate cancer xenografts in nude mice. Although improvements in the bioavailability are necessary, L-39 is a potential lead compound with this profile as an inhibitor of prostate cancer growth. © 2000 Cancer Research Campaign
- Published
- 2000
14. Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo
- Author
-
Yang Liu, Angela Brodie, Dmitry N. Grigoryev, Vincent C. O. Njar, Ivo P. Nnane, and Brian J. Long
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,Mice, SCID ,Biology ,urologic and male genital diseases ,Antiandrogen ,Flutamide ,Mice ,chemistry.chemical_compound ,Prostate cancer ,azolyl steroids ,SCID mice ,Internal medicine ,LNCaP ,Tumor Cells, Cultured ,medicine ,Animals ,Humans ,Enzyme Inhibitors ,17α-hydroxylase/C17,20-lyase inhibitors ,Metribolone ,Prostatic Neoplasms ,Steroid 17-alpha-Hydroxylase ,Regular Article ,Prostate-Specific Antigen ,Androgen ,medicine.disease ,androgens synthesis ,Androgen receptor ,Endocrinology ,Oncology ,chemistry ,Cancer cell ,Cancer research ,Steroids ,Cell Division ,LNCaP cells - Abstract
Our laboratory has been developing new inhibitors of a key regulatory enzyme of testicular and adrenal androgen synthesis 17alpha-hydroxylase/C(17,20)-lyase (P450c17), with the aim of improving prostate cancer treatment. We designed and evaluated two groups of azolyl steroids: delta5-non-competitive inhibitors (delta5NCIs), VN/63-1, VN/85-1, VN/87-1 and their corresponding delta4 derivatives (delta4NCIs), VN/107-1, VN/108-1 and VN/109-1. The human P450c17 gene was transfected into LNCaP human prostate cancer cells, and the resultant LNCaP-CYP17 cells were utilized to evaluate the inhibitory potency of the new azolyl steroids. VN/85-1 and VN/108-1 had the lowest IC50 values of 1.25 +/- 0.44 nM and 2.96 +/- 0.78 nM respectively, which are much lower than that of the known P450 inhibitor ketoconazole (80.7 +/- 1.8 nM). To determine whether the compounds had direct actions on proliferation of wild-type LNCaP cells, cell growth studies were performed. All of the delta5NCIs and VN/108-1 blocked the growth-stimulating effects of androgens. In steroid-free media, the delta5NCIs decreased the proliferation of LNCaP cells by 35-40%, while all of the delta4NCIs stimulated LNCaP cells growth 1.5- to 2-fold. In androgen receptor (AR) binding studies, carried out to determine the mechanism of this effect, all of the delta4NCIs (5 microM) displaced 77-82% of synthetic androgen R1881 (5 nM) from the LNCaP AR. The anti-androgen flutamide and the delta5NCIs displaced 53% and 32-51% of R1881 bound to AR respectively. These results suggested that the delta5NCIs may also be acting as anti-androgens. We further evaluated our inhibitors in male severe combined immunodeficient mice bearing LNCaP tumour xenografts. In this model VN/85-1 was as effective as finasteride at inhibiting tumor growth (26% and 28% inhibition, respectively) and the inhibitory effect of VN/87-1 was similar to that of castration (33% and 36% inhibition respectively). These results suggest that VN/85-1 and VN/87-1 may be potential candidates for treatment of prostate cancer.
- Published
- 1999
15. Cytochrome P450c17-ExpressingEscherichia colias a First-Step Screening System for 17α-Hydroxylase- C17,20-lyase Inhibitors
- Author
-
Angela Brodie, Dmitry N. Grigoryev, James L. Mohler, Vincent C. O. Njar, Brian J. Long, Xin Wang, Katsuya Kato, and Yang Zhi Ling
- Subjects
Male ,endocrine system ,Cytochrome ,Biophysics ,Transfection ,medicine.disease_cause ,Biochemistry ,law.invention ,Acetic acid ,chemistry.chemical_compound ,law ,Microsomes ,Testis ,Escherichia coli ,medicine ,Humans ,Molecular Biology ,Chromatography, High Pressure Liquid ,chemistry.chemical_classification ,biology ,Steroid 17-alpha-Hydroxylase ,Cytochrome P450 ,Cell Biology ,biology.organism_classification ,Molecular biology ,Recombinant Proteins ,Enzyme ,chemistry ,biology.protein ,Recombinant DNA ,Microsome ,Bacteria - Abstract
We have designed and synthesized a number of cytochrome P450 17alpha-hydroxylase-C17,20-lyase (P450c17) inhibitors with the aim of inhibiting androgen synthesis. To select the most potent inhibitors, we initially used human testicular microsomes, which have a high level of expression of this enzyme. However, due to lack of availability of human tissue and variability among the samples, we utilized recombinant human enzyme expressed in Escherichia coli. We designed a simple and economical protocol based on the report that recombinant bovine P450c17 can be functionally active in live bacteria. In the assay we report here, we substituted high-performance liquid chromatography product isolation with a rapid biochemical acetic acid releasing assay and utilized intact P450c17-expressing E. coli for the source of the enzyme. Enzymatic parameters of the bacterial system (Km = 5.1 x 10(-7) M, Vmax = 15.0 pmol/min/mg) were similar to those of human testicular microsomes (Km = 4.8 x 10(-7) M, Vmax = 40.0 pmol/min/mg), and our compounds displayed a similar pattern of inhibition in both systems. This new system is a fast, reliable, and reproducible method for screening P450c17 inhibitors. Furthermore, it eliminates our dependence on human tissue and potential data fluctuations caused by variations in enzymatic activity between donors.
- Published
- 1999
16. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity
- Author
-
Angela Brodie, Syreeta L. Tilghman, Wei Yue, Dmitry N. Grigoryev, Brian J. Long, and Apinya Thiantanawat
- Subjects
Placenta ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Biochemistry ,Endocrinology ,Tumor Cells, Cultured ,polycyclic compounds ,Choriocarcinoma ,Enzyme Inhibitors ,Aromatase ,skin and connective tissue diseases ,Fulvestrant ,Cells, Cultured ,Estradiol ,biology ,Aromatase Inhibitors ,Letrozole ,Estrogen Antagonists ,Biological activity ,Molecular Medicine ,Female ,Cell Division ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug ,medicine.medical_specialty ,medicine.drug_class ,Anastrozole ,Breast Neoplasms ,Microsomes ,Internal medicine ,Nitriles ,medicine ,Humans ,RNA, Messenger ,Molecular Biology ,DNA Primers ,Base Sequence ,Androstenedione ,Cell Biology ,Fibroblasts ,Triazoles ,Antiestrogen ,Estrogen ,biology.protein ,Tamoxifen - Abstract
Two types of endocrine therapy that have been successfully applied to patients with hormone-dependent breast cancer are the non-steroidal antiestrogen tamoxifen, and inhibitors of aromatase, the enzyme that synthesizes estrogens. The major drawback with tamoxifen is that it acts as a partial estrogen-agonist and this is believed to mediate, at least in part, acquired tumor resistance to the drug as well as endometrial hyperplasia and carcinoma in some patients. The newer and more potent antiestrogen ICI 182,780 is a steroidal molecule that is devoid of estrogenic activity. We now report that ICI 182,780 is also an inhibitor of aromatase activity in fibroblasts isolated from the normal human breast as well as other carcinoma cell lines that express aromatase (MCF-7Ca breast cancer and JEG-3 choriocarcinoma). ICI 182,780 (1 microM) did not affect aromatase activity levels in human placental microsomes and only inhibited aromatase activity in each of the cell lines following a prolonged incubation period. In the fibroblasts, inhibition of aromatase activity by ICI 182,780 was shown to be time and dose-dependent. In contrast, tamoxifen and 17beta-estradiol were shown to have no effect on aromatase activity levels. ICI 182,780 inhibited aromatase activity levels with IC50 values of 16.80 nM in MCF-7Ca cells, 125.50 nM in JEG-3 cells and 386.1 nM in breast fibroblasts. These values were compared to those for known aromatase inhibitors, and in each of the cell lines the order of potency was letrozole>4-OHA>anastrozole>ICI 182,780. The inhibition of aromatase activity by ICI 182,780 was sustained even after the antiestrogen was removed from the cells indicating that ICI 182,780 may be remaining bound to the enzyme. Although ICI 182,780 had no effect on the proliferation of the fibroblasts, or JEG-3 cells, it significantly inhibited the growth of MCF-7Ca cells. This growth inhibition appeared to be due to the antiestrogenic activity of ICI 182,780 and not to its aromatase inhibiting effects. ICI 182,780 did not inhibit aromatase activity by down-regulating levels of the aromatase transcript. These results show that in addition to being a potent antiestrogen, ICI 182,780 is also an inhibitor of cellular aromatase activity, and suggest that by interfering with the actions of estrogen by two distinct mechanisms, ICI 182,780 may be a suitable drug for treating patients with hormone-dependent breast cancer.
- Published
- 1998
17. Aromatase expression in the human breast
- Author
-
Brian J. Long, Angela Brodie, and Qing Lu
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Stromal cell ,Adolescent ,Antibodies, Neoplasm ,medicine.drug_class ,Mammary gland ,Immunocytochemistry ,Breast Neoplasms ,In situ hybridization ,Polymerase Chain Reaction ,Gene Expression Regulation, Enzymologic ,Aromatase ,Breast cancer ,Internal medicine ,medicine ,Humans ,Breast ,RNA, Messenger ,In Situ Hybridization ,Testosterone ,DNA Primers ,biology ,Antibodies, Monoclonal ,medicine.disease ,Immunohistochemistry ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Endocrinology ,Oncology ,Estrogen ,biology.protein ,Cancer research ,Female - Abstract
The plasma levels of free estradiol are very low in postmenopausal women. However, concentrations of estrogens within breast tissue have been reported to be higher than in plasma and similar to plasma concentrations in premenopausal women. One mechanism by which this may occur is for breast cells to synthesize estrogens themselves and produce high concentrations locally. Thus, tumor aromatase may be a significant source of estrogen which stimulates tumor growth. To address the question of the importance of this pathway, we have investigated the expression of aromatase within the normal breast and breast cancers. Because conventional biochemical assays for measuring aromatase activity require relatively large amounts of tissue, we developed an immunocytochemical method using a monoclonal antibody to determine the expression of aromatase. The method can be applied to sections of tumors embedded in paraffin blocks as routinely prepared for pathology. Since we have previously shown that mRNA for aromatase (P450 arom) and the protein are expressed in the same cells of the human placenta, we used in situ hybridization of sequence specific probes to P450 arom mRNA in breast tissue as one method to verify the specificity of the immunocytochemical detection of the enzyme. Both immunocytochemistry and in situ hybridization identified aromatase enzyme and mRNA expression in the epithelial cells of the terminal ductal lobula units (TDLU) and surrounding stromal cells of the normal human breast, and in the tumor epithelial cells and stromal cells of breast cancers. In addition, evidence for the functional significance of tumor aromatase was indicated by a correlation between aromatase activity and expression of proliferating cell nuclear antigen (PCNA) in the tumor, and by increased thymidine incorporation into DNA in response to testosterone in tumors in histoculture which had high aromatase activity but not in those with low activity. The findings suggests that estrogen produced locally is important in enhancing proliferation of the tumor.
- Published
- 1998
18. Novel 17-Azolyl Steroids, Potent Inhibitors of Human Cytochrome 17α-Hydroxylase-C17,20-lyase (P45017α): Potential Agents for the Treatment of Prostate Cancer
- Author
-
Vincent C. O. Njar, Dmitry N. Grigoryev, Angela Brodie, Katsuya Kato, Ivo P. Nnane, and Brian J. Long
- Subjects
Male ,medicine.medical_treatment ,Antineoplastic Agents ,Steroid ,Rats, Sprague-Dawley ,Structure-Activity Relationship ,5 Alpha-Reductase Inhibitor ,5-alpha Reductase Inhibitors ,Microsomes ,Testis ,Drug Discovery ,LNCaP ,Tumor Cells, Cultured ,medicine ,Animals ,Humans ,Structure–activity relationship ,Enzyme Inhibitors ,chemistry.chemical_classification ,biology ,Chemistry ,Imidazoles ,Prostatic Neoplasms ,Steroid 17-alpha-Hydroxylase ,Cytochrome P450 ,Androgen Antagonists ,Triazoles ,Rats ,Androstadienes ,Ketoconazole ,Enzyme ,Biochemistry ,Enzyme inhibitor ,biology.protein ,Molecular Medicine ,Azole - Abstract
A new synthetic route to a variety of novel delta 16-17-azolyl steroids is described: it involves the nucleophilic vinylic "addition-elimination" substitution reaction of 3 beta-acetoxy-17-chloro-16-formylandrosta-5,16-diene (2) and azolyl nucleophiles. Some of these novel delta 16-17-azolyl steroids, 6, 17, 19, and 27-29, prepared in good overall yields, are very potent inhibitors of human and rat testicular P450(17) alpha. They are shown to be noncompetitive and appear to be slow-binding inhibitors of human P450(17) alpha. The most potent compounds are 3 beta-hydroxy-17-(1H-imidazol-1-yl)androsta-5,16-diene (17), 3 beta-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,-16-diene (19), and 17-(1H-imidazol-1-yl)androsta-4,16-dien-3-one (28), with Ki values of 1.2, 1.4, and 1.9 nM, respectively, being 20-32 times more potent than ketoconazole (Ki = 38 nM). Spectroscopic studies with a modified form of human P450(17) alpha indicate that the inhibition process involves binding of steroidal azole nitrogen to the heme iron of the enzyme. Furthermore, some of these potent P450(17) alpha inhibitors (27-29) are also powerful inhibitors of steroid 5 alpha-reductase, and others (17 and 19) appear to exhibit strong antiandrogenic activity in cultures of the LNCaP human prostatic cancer cell line. These novel compounds with impressive dual biological activities make them strong candidates for development as therapeutic agents for treatment of prostate cancer and other disease states which depend on androgens.
- Published
- 1998
19. Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER
- Author
-
David P. Rose and Brian J. Long
- Subjects
Cancer Research ,medicine.medical_specialty ,Genetic Vectors ,Cell ,Estrogen receptor ,Breast Neoplasms ,Enzyme-Linked Immunosorbent Assay ,Biology ,Transfection ,Gene Expression Regulation, Enzymologic ,Cell Line ,Downregulation and upregulation ,Epidermal growth factor ,Internal medicine ,Tumor Cells, Cultured ,medicine ,Humans ,Neoplasm Invasiveness ,Epidermal Growth Factor ,Estradiol ,Urokinase-Type Plasminogen Activator ,Molecular biology ,Recombinant Proteins ,Gene Expression Regulation, Neoplastic ,Endocrinology ,medicine.anatomical_structure ,Receptors, Estrogen ,Oncology ,Cell culture ,Cancer cell ,Female ,Plasminogen activator - Abstract
We assessed the invasive capacities and expression of urokinase-type plasminogen activator (uPA) in the estrogen receptor (ER) negative MDA-MB-231 cell line, and the same cell transfected with an ER expression vector (S30 cells) in response to 17 beta-estradiol (E2; 1 nM) and epidermal growth factor (EGF; 1 ng/ml and 10 ng/ml). The invasive potential of S30 cells was only 50% that of MDA-MB-231 cells and was further reduced by E2. EGF increased the invasiveness of S30 cells, but was unable to reverse the inhibitory effects of E2. Invasion of MDA-MB-231 cells was unaffected by E2 or EGF. EGF increased uPA secretion from both cell lines, as determined by ELISA and zymography, and this correlated with increased expression of uPA mRNA. uPA expression in MDA-MB-231 cells was unaffected by E2; however, S30 cells responded to E2 with downregulation of uPA at both the protein and mRNA levels.
- Published
- 1996
20. Abstract 4788: Discovery of potent and selective inhibitors of ERK1/2 with a unique mechanism of action
- Author
-
Xiaolei Gao, Gerald W. Shipps, Liang Zhu, Brian J. Long, Tong Wang, Ahmed A. Samatar, Babu Sobhana Boga, Kiran Muppalla, Donnar Carr, Yongqi Deng, Alan Hruza, Hugh Y. Zhu, Mehul D. Patel, Alan B. Cooper, Li Xiao, and Yang Nan
- Subjects
Cancer Research ,Oncology ,Mechanism of action ,Chemistry ,medicine ,medicine.symptom ,Neuroscience - Abstract
Activation of the RAS/MAPK pathway occurs via a cascade of protein phosphorylation events which culminate in the phosphorylation & activation of ERK 1/2. Aberrant activation of this pathway has been demonstrated in several human tumor types. Inhibitors of this pathway in clinical development target upstream kinases, BRAF or MEK. Only a few ERK 1/2 has been reported. The goal of the ERK program was to develop a targeted therapy that is guided by a clear patient selection / responder identification plan based on BRAF and K/NRAS mutations. Utilizing an affinity based high-throughput screening strategy (ALIS), we discover a novel class of small molecule ERK 1/2 inhibitors. Optimization of this chemical series led to the discovery of SCH 772984, which is highly selective ERK1/2 inhibitor, inhibiting cell proliferation selectively in tumor cell lines with an activated MAPK pathway and causes significant tumor regression in vivo in BRAF & RAS mutant xenograft models. Based on insights gained through crystallographic analysis, SCH 772984 and related compounds have a unique ERK binding mode which results in a novel dual mechanism of inhibition, blocking ERK phosphorylation by MEK as well as inhibiting ERK kinase activity. This novel mechanism enables the use of ERK phosphorylation as a target engagement biomarker. Biological differences between pathway inhibition at the level or ERK vs. inhibition of upstream kinases are being examined. The SAR and crystal structures of this series ERK inhibitors will be reported. Citation Format: Yongqi Deng, Ahmed Samatar, Gerald Shipps, Alan Cooper, Brian Long, Donnar Carr, Li Xiao, Alan Hruza, Tong Wang, Liang Zhu, Yang Nan, Mehul Patel, Kiran Muppalla, Hugh Zhu, Babu Sobhana Boga, Xiaolei Gao. Discovery of potent and selective inhibitors of ERK1/2 with a unique mechanism of action. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4788.
- Published
- 2016
21. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line
- Author
-
Brian J. Long, M. Lynch, H. van den Berg, and B. McKibben
- Subjects
Cancer Research ,medicine.medical_specialty ,Cell ,Drug Resistance ,Breast Neoplasms ,In Vitro Techniques ,ErbB Receptors ,Epidermal growth factor ,Internal medicine ,Progesterone receptor ,Tumor Cells, Cultured ,medicine ,Humans ,Epidermal growth factor receptor ,skin and connective tissue diseases ,Receptor ,Epidermal Growth Factor ,biology ,Antiestrogen ,Tamoxifen ,Endocrinology ,medicine.anatomical_structure ,Receptors, Estrogen ,Oncology ,biology.protein ,Receptors, Progesterone ,Research Article ,medicine.drug - Abstract
We have examined the expression of receptors for epidermal growth factor (EGFR) by the ZR-75-1 human breast cancer cell line and tamoxifen resistant (ZR-75-9al 8 microM) and oestrogen independent/tamoxifen sensitive (ZR-PR-LT) variants. The parent line expressed a single class of high affinity binding sites (4,340 +/- 460 receptors/cell; Kd 0.23 +/- 0.04 nM). ZR-75-9al 8 microM cells, routinely maintained in medium containing 8 microM tamoxifen, were negative for oestrogen receptor (ER) and progesterone receptor (PGR) and expressed a markedly increased number of EGFR (14,723 +/- 2116 receptors/cell). Receptor affinity was unchanged. Time dependent reversal of the tamoxifen resistant phenotype was accompanied by a return to ER and PGR positivity and a fall in EGFR numbers to parent cell levels. In contrast ZR-PR-LT cells had a greatly reduced EGFR content (803 +/- 161 receptors/cell) accompanying elevated PGR numbers. Pre-treatment of these cells with suramin or mild acid stripping failed to expose receptors which may have been occupied by endogenously produced ligand. Increased proliferation of ZR-75-1 cells treated with EGFR (0.01-10 ng ml-1) was only observed in serum-free medium lacking insulin and oestradiol. Under these conditions untreated cells failed to proliferate. Both variant lines continued to proliferate in serum free medium in the absence or presence of insulin and oestradiol but failed to respond to exogenous EGF.
- Published
- 1992
22. Ultra-performance hydrophilic interaction liquid chromatography/tandem mass spectrometry for the determination of everolimus in mouse plasma
- Author
-
Yunsheng, Hsieh, Gerica, Galviz, and Brian J, Long
- Subjects
Sirolimus ,Mice ,Tandem Mass Spectrometry ,Animals ,Everolimus ,Sensitivity and Specificity ,Chromatography, Liquid - Abstract
Ultra-performance hydrophilic interaction liquid chromatography (UPHILIC) interfaced with the electrospray ionization (ESI) source of a tandem mass spectrometer (MS/MS) was developed for the simultaneous determination of everolimus in mouse plasma samples. UPHILIC was performed on a sub-2 microm bare silica particle packing with the column pressure under traditional high-performance liquid chromatography (HPLC) to allow fast separation of pharmaceutical compounds within a chromatographic analysis time of 1 min. This UPHILIC technology is comparable with reversed-phase ultra-performance liquid chromatography (RPUPLC) in terms of chromatographic efficiency but demands neither expensive ultra-high-pressure instrumentation nor new laboratory protocols. With the ESI source, multiple reaction monitoring (MRM) of the ammoniated adduct ions of the analyte was used for tandem mass spectrometric detection. The retention mechanism profiles of the test compounds under HILIC conditions were explored. The influences of experimental factors such as the compositions of mobile phases on the chromatographic performance and the ionization efficiency of the test compounds in positive ion mode were investigated. A UPHILIC/MS/MS approach following a protein precipitation procedure was applied for the quantitative determination of everolimus at the low ng/mL region in support of a pharmacodynamic study. The analytical results obtained by the UPHILIC/MS/MS approach were fond to be in good agreement with those obtained by the RPUPLC/MS/MS method in terms of assay sample throughput, sensitivity and accuracy.
- Published
- 2009
23. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity
- Author
-
Andrea D, Basso, Asra, Mirza, Gongjie, Liu, Brian J, Long, W Robert, Bishop, and Paul, Kirschmeier
- Subjects
Bridged-Ring Compounds ,Alkyl and Aryl Transferases ,Pyridines ,Recombinant Fusion Proteins ,TOR Serine-Threonine Kinases ,Neuropeptides ,Protein Prenylation ,Antineoplastic Agents ,Tamoxifen ,Piperidines ,Caspases ,Cell Line, Tumor ,Neoplasms ,Animals ,Farnesyltranstransferase ,Humans ,Ras Homolog Enriched in Brain Protein ,Taxoids ,RNA, Messenger ,Phosphorylation ,Protein Kinases ,Monomeric GTP-Binding Proteins ,Signal Transduction - Abstract
Lonafarnib (SCH66336) is a farnesyl transferase inhibitor (FTI) that inhibits the post-translational lipid modification of H-Ras and other farnesylated proteins. K- and N-Ras are also substrates of farnesyl transferase; however, upon treatment with FTIs, they are alternatively prenylated by geranylgeranyl transferase-1. Despite the failure to abrogate prenylation of K- and N-Ras, growth of many tumors in preclinical models is inhibited by FTIs. This suggests that the anti-proliferative action of FTIs is dependent on blocking the farnesylation of other proteins. Rheb (Ras homologue enriched in brain) is a farnesylated small GTPase that positively regulates mTOR (mammalian target of rapamycin) signaling. We found that Rheb and Rheb2 mRNA were elevated in various tumor cell lines relative to normal cells. Peptides derived from the carboxyl termini of human Rheb and Rheb2 are in vitro substrates for farnesyl transferase but not geranylgeranyl transferase-1. Rheb prenylation in cell culture was completely inhibited by SCH66336, indicating a lack of alternative prenylation. SCH66336 treatment also inhibited the phosphorylation of S6 ribosomal protein, a downstream target of Rheb and mTOR signaling. SCH66336 did not inhibit S6 phosphorylation in cells expressing Rheb-CSVL, a mutant construct of Rheb designed to be geranylgeranylated. Importantly, expression of Rheb-CSVL also abrogated SCH66336 enhancement of tamoxifen- and docetaxel-induced apoptosis in MCF-7 breast cancer cells and ES-2 ovarian cancer cells, respectively. Further, inhibition of Rheb signaling by rapamycin treatment, small interfering RNA, or dominant negative Rheb enhanced tamoxifen- and docetaxel-induced apoptosis, similar to FTI treatment. These studies demonstrated that Rheb is modified by farnesylation, is not a substrate for alternative prenylation, and plays a role in SCH66336 enhancement of the anti-tumor response to other chemotherapeutics.
- Published
- 2005
24. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation
- Author
-
Angela Brodie, Brian J. Long, Gauri Sabnis, and Danijela Jelovac
- Subjects
Cancer Research ,medicine.medical_specialty ,Neoplasms, Hormone-Dependent ,Anastrozole ,Estrogen receptor ,Breast Neoplasms ,Biology ,Protein Serine-Threonine Kinases ,chemistry.chemical_compound ,Growth factor receptor ,Exemestane ,Internal medicine ,Cell Line, Tumor ,Proto-Oncogene Proteins ,medicine ,Humans ,Growth factor receptor inhibitor ,Neoplasm Invasiveness ,Receptors, Growth Factor ,skin and connective tissue diseases ,Estrogen receptor beta ,Fulvestrant ,Estrogens ,Receptor Cross-Talk ,Antiestrogen ,Up-Regulation ,Enzyme Activation ,Endocrinology ,Oncology ,chemistry ,Receptors, Estrogen ,Disease Progression ,Proto-Oncogene Proteins c-akt ,medicine.drug ,Signal Transduction - Abstract
To study the long-term effects of estrogen deprivation on breast cancer, MCF-7Ca human estrogen receptor–positive breast cancer cells stably transfected with human aromatase gene were cultured in the steroid-depleted medium for 6 to 8 months until they had acquired the ability to grow. Proliferation of these cells (UMB-1Ca) was accompanied by increased expression of human epidermal growth factor receptor 2, increased activation of AKT through phosphorylation at Ser473 and Thr308, and increased invasion compared with parental MCF-7Ca cells. Estrogen receptor expression was also increased 5-fold. Although growth was inhibited by the antiestrogen fulvestrant, the IC50 was 100-fold higher than for parental MCF-7Ca cells. Aromatase inhibitor letrozole also inhibited growth at 10,000-fold higher concentration than required for MCF-7Ca cells, whereas anastrozole, exemestane, formestane, and tamoxifen were ineffective at 100 nmol/L. Growth of UMB-1Ca cells was inhibited by phosphatidylinositol 3-kinase inhibitor wortmannin (IC50 ∼25 nmol/L) and epidermal growth factor receptor kinase inhibitor gefitinib (ZD 1839; IC50 ∼10 μmol/L) whereas parental MCF-7Ca cells were insensitive to these agents. Concomitant treatment of UMB-1Ca cells with the signal transduction inhibitors and anastrozole and tamoxifen restored their growth inhibitory effects. These studies show that estrogen deprivation results in up-regulation of growth factor signaling pathways, which leads to a more aggressive and hormone refractory phenotype. Cross-talk between ER and growth factor signaling was evident as inhibition of these pathways could restore estrogen responsiveness to these cells.
- Published
- 2005
25. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model
- Author
-
James N. Ingle, Luciana Macedo, Danijela Jelovac, Brian J. Long, Venkatesh D. Handratta, Angela M. H. Brodie, and Olga Goloubeva
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Neoplasms, Hormone-Dependent ,Time Factors ,medicine.drug_class ,Mice, Nude ,Breast Neoplasms ,Mammary Neoplasms, Animal ,Pharmacology ,chemistry.chemical_compound ,Mice ,Random Allocation ,Breast cancer ,Exemestane ,Internal medicine ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,Nitriles ,medicine ,Animals ,Humans ,skin and connective tissue diseases ,Mice, Inbred BALB C ,Aromatase inhibitor ,Dose-Response Relationship, Drug ,business.industry ,Letrozole ,Triazoles ,medicine.disease ,Antiestrogen ,Androstadienes ,Postmenopause ,Tamoxifen ,chemistry ,Estrogen ,Disease Progression ,Female ,business ,Neoplasm Transplantation ,Steroidal Aromatase Inhibitor ,medicine.drug - Abstract
Purpose: To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer. We also determined the effects of these agents in sequential second-line therapy and the effect of the nonsteroidal aromatase inhibitor letrozole on tumors that progressed on the above treatments. Experimental: Aromatase-transfected human estrogen receptor-positive breast cancer cells (MCF-7Ca) were grown as tumors in ovariectomized athymic mice. Animals received subcutaneous injection with vehicle, tamoxifen, exemestane, tamoxifen plus exemestane, and letrozole. Tumor volumes were measured weekly. Results: All treatments were effective initially in suppressing tumor growth as first-line therapy compared with vehicle treatment. Exemestane suppressed tumor growth to a greater extent than tamoxifen. However, the combination of tamoxifen plus exemestane was more effective than either drug alone. After tumor volumes doubled on initial treatment, the mice were crossed over to receive exemestane or tamoxifen. Tumor growth slowed briefly in mice treated with tamoxifen and crossed over to exemestane, but tumor growth continued unabated in those changed from exemestane to tamoxifen. However, letrozole was effective in both groups as third-line therapy for a limited period. Letrozole as initial single agent was the best overall treatment in terms of the degree of tumor suppression and the length of effectiveness of treatment. Conclusion: Exemestane was more effective in controlling tumor growth than tamoxifen. In addition, the combination of exemestane plus tamoxifen was clearly more effective than sequential use of these agents in the tumor model. However, the nonsteroidal aromatase inhibitor letrozole as first-line therapy was overall the most effective treatment in controlling tumor growth.
- Published
- 2004
26. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model
- Author
-
Vincent C. O. Njar, Ritesh Kataria, Angela Brodie, Brian J. Long, Danijela Jelovac, Venkatesh D. Handratta, and Ivo P. Nnane
- Subjects
Male ,Time Factors ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Transplantation, Heterologous ,Mice, SCID ,Pharmacology ,Biochemistry ,Prostate cancer ,chemistry.chemical_compound ,Mice ,Endocrinology ,Pharmacokinetics ,Prostate ,LNCaP ,medicine ,Animals ,Humans ,Androstanols ,Molecular Biology ,Chromatography, High Pressure Liquid ,Dose-Response Relationship, Drug ,business.industry ,Finasteride ,Imidazoles ,Prostatic Neoplasms ,Steroid 17-alpha-Hydroxylase ,Cell Biology ,Triazoles ,medicine.disease ,Androgen ,Bioavailability ,Androstadienes ,Regimen ,medicine.anatomical_structure ,chemistry ,Molecular Medicine ,business - Abstract
A facile preparation of azolyl steroids, VN/85-1 and VN/87-1 (potent inhibitors of CYP17) has been developed. This process without tedious chromatographic separations improved the overall yields from 55 and 45% to 70 and 65% for VN/85-1 and VN/87-1, respectively. Pharmacokinetic studies of VN/85-1 were conducted in male SCID mice. Following subcutaneous (s.c.) administration of 100 mg/kg of VN/85-1, peak plasma level of 16.73 μg/ml occurred after 45 min, and the compound was cleared rapidly with a t 1/2 of 52.34 min. The bioavailability of VN/85-1 after s.c. administration was 83.0%. VN/85-1 was also rapidly metabolized to the corresponding 3-oxo-4-ene analog, 17-(1 H -imidazol-1-yl)androsta-4,16-diene-3-one (VN/108-1). In our attempt to optimize the anti-tumor efficacy of these two CYP17 inhibitors, we studied their anti-tumor efficacies in male SCID mice bearing LNCaP tumor xenografts, utilizing various drug doses and drug scheduling. Three times a day dose regimen (3× dose regimen) of VN/85-1 was more effective than a once daily dose. In contrast, 3× dose regimen doses of VN/87-1 were less effective than the once daily dose. However, at their effective dosage regimes, VN/85-1 and VN/87-1 were each as effective as castration and more effective than finasteride or casodex, an anti-androgen used for prostate cancer (PC) therapy. For all of the treatments, there was a strong correlation between the tumor volumes and other associated parameters, such as, tumor weights, and serum testosterone (T) and PSA levels. These results indicate that VN/85-1 or VN/87-1 may be useful in the treatment of hormone-dependent prostate cancer.
- Published
- 2004
27. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens
- Author
-
Apinya, Thiantanawat, Brian J, Long, and Angela M, Brodie
- Subjects
Cyclin-Dependent Kinase Inhibitor p21 ,Ovariectomy ,Down-Regulation ,Mice, Nude ,Apoptosis ,Breast Neoplasms ,Transfection ,Mice ,Aromatase ,Estrogen Receptor Modulators ,Cell Line, Tumor ,Cyclins ,Proto-Oncogene Proteins ,Animals ,Humans ,Enzyme Inhibitors ,bcl-2-Associated X Protein ,Mice, Inbred BALB C ,Aromatase Inhibitors ,Cell Cycle ,Xenograft Model Antitumor Assays ,Up-Regulation ,Enzyme Activation ,Proto-Oncogene Proteins c-bcl-2 ,Caspases ,Female ,Tumor Suppressor Protein p53 ,Signal Transduction - Abstract
Aromatase inhibitors have recently been reported to be more effective than the antiestrogen tamoxifen (Tam) in treating breast cancer. Here, we studied the mechanisms and signaling pathways of cell growth, cell cycle progression, and apoptosis induced by three aromatase inhibitors: letrozole (Let), anastrozole, and 4-hydroxyandrostenedione in comparison with estrogen withdrawal (E2W) and antiestrogens Tam and faslodex. Estrogen-dependent human breast cancer cells stably transfected with aromatase (MCF-7Ca) were used. All treatments induced growth suppression and cell cycle arrest at the G(0)-G(1) phase that was associated with up-regulation of p53 and p21 protein and mRNA levels and down-regulation of cyclin D1 and c-myc mRNA. The apoptotic index was increased 4-7 fold, Bcl-2 protein expression decreased, Bax increased, and caspase-9, caspase-6, and caspase-7 were activated but not caspase-3 and caspase-8. Let and E2W caused regression of tumors of MCF-7Ca cells grown in nude mice and increased the number of cells undergoing apoptosis. In contrast, Tam and faslodex did not induce tumor regression and a lower number of apoptotic cells was detected. Cleavage of poly(ADP-ribose) polymerase was detected. Treatment with Let, Tam, or E2W resulted in a dose- and time-dependent increase in active caspase-7 and up-regulation of p53 and p21 protein. Although the mechanisms involved appeared to be similar for antiestrogens and aromatase inhibitors, the most significant effects occurred with Let, which were significantly greater than with E2W and consistent with marked effects of Let on tumor and cell growth.
- Published
- 2003
28. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens
- Author
-
Angela, Brodie, Danijela, Jelovac, and Brian J, Long
- Subjects
Mice, Inbred BALB C ,Neoplasms, Hormone-Dependent ,Aromatase Inhibitors ,Drug Evaluation, Preclinical ,Estrogen Antagonists ,Mammary Neoplasms, Experimental ,Disease Models, Animal ,Mice ,Aromatase ,Tumor Cells, Cultured ,Animals ,Humans ,Drug Therapy, Combination ,Female ,Enzyme Inhibitors - Abstract
We have developed a tumor model for studying the effects of aromatase inhibitors and antiestrogens in vivo. The model simulates postmenopausal breast cancer patients with estrogen-dependent tumors. This model utilizes human estrogen-dependent breast cancer cells transfected with the aromatase gene (MCF-7(CA)), which are inoculated in Matrigel s.c. into ovariectomized nude mice. The estrogen receptor-positive cells produce sufficient estrogen by aromatization to stimulate their proliferation and the formation of tumors in the mice. Using several different strategies, we have compared the aromatase inhibitors (letrozole and anastrozole) with antiestrogens (tamoxifen and fulvestrant). Aromatase inhibitors were more effective than tamoxifen and were more effective alone than when combined with antiestrogens. In addition, letrozole had a longer duration of effect than tamoxifen. The possibility of delaying the development of resistance to antiestrogens and aromatase inhibitors was investigated by alternating letrozole with tamoxifen every 4 weeks. However, although alternating treatment proved more effective than tamoxifen alone (tumors doubled in 16 weeks), tumors doubled in volume at about 18 weeks when treatment began with tamoxifen. When treatment started with letrozole and alternated with tamoxifen, tumors doubled in volume in about 22 weeks. However, tumors of mice treated with letrozole alone did not double in size until 35 weeks. These results demonstrate that this aromatase inhibitor is more effective and has a longer duration of response as a single agent than tamoxifen or in combination with tamoxifen.
- Published
- 2003
29. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model
- Author
-
Brian J, Long, Danijela, Jelovac, Apinya, Thiantanawat, and Angela M, Brodie
- Subjects
Mice, Inbred BALB C ,Neoplasms, Hormone-Dependent ,Estradiol ,Aromatase Inhibitors ,Estrogen Antagonists ,Mammary Neoplasms, Experimental ,Mice, Nude ,In Vitro Techniques ,Triazoles ,Disease Models, Animal ,Mice ,Tamoxifen ,Aromatase ,Receptors, Estrogen ,Letrozole ,Nitriles ,Tumor Cells, Cultured ,Animals ,Humans ,Female ,Enzyme Inhibitors ,Fulvestrant - Abstract
The aromatase inhibitors letrozole and anastrozole have been approvedrecently as first-line treatment options for hormone-dependent advanced breast cancer. Although it is established that a proportion of patients who relapse on first-line tamoxifen therapy show additional responses to aromatase inhibitors, it has not been determined whether tumors that acquire resistance to aromatase inhibitors in the first line remain sensitive to second-line therapy with antiestrogens. The aim of this study was to determine whether aromatase-transfected and hormone-dependent MCF-7Ca human breast cancer cells remain sensitive to antiestrogens after: (a) long-term growth in steroid-depleted medium in vitro; and (b) long-term treatment with the aromatase inhibitor letrozole in vivo.In the first approach, a variant of the MCF-7Ca human breast cancer cell line was selected that had acquired the ability to grow in estrogen-depleted medium after 6-8 months of culture. Steroid-deprived UMB-1Ca cells were analyzed for aromatase activity levels, hormone receptor levels, and sensitivity to estrogens and antiestrogens in vitro and in vivo. In the second approach, established MCF-7Ca breast tumor xenografts were treated with letrozole 10 microg/day for 12 weeks followed by 100 microg/day for 25 weeks until tumors acquired the ability to proliferate in the presence of the drug. Long-term letrozole-treated tumors were then transplanted into new mice, and the effects of antiestrogens and aromatase inhibitors on tumor growth were determined.Steroid-deprived UMB-1Ca breast cancer cells continued to express aromatase activity at levels comparable with the parental cell line. However, compared with MCF-7Ca cells, UMB-1Ca cells expressed elevated levels of functionally active estrogen receptor. The growth of UMB-1Ca cells in vitro was inhibited by the antiestrogens tamoxifen and faslodex and tumor growth in vivo was inhibited by tamoxifen. In the second approach, the time for MCF-7Ca tumor xenografts to approximately double in volume after being treated sequentially with the increasing doses of letrozole was thirty-seven weeks. Long-term letrozole-treated tumors continued to express functionally active aromatase. When transplanted into new mice, growth of the long-term letrozole-treated tumors was slowed by tamoxifen and inhibited more effectively by faslodex. Tumor growth was refractory to the aromatase inhibitors anastrozole and formestane but, surprisingly, showed sensitivity to letrozole.Steroid-deprived UMB-1Ca human breast cancer cells selected in vitro and long-term letrozole-treated MCF-7Ca breast tumor xenografts remain sensitive to second-line therapy with antiestrogens and, in particular, to faslodex. This finding is associated with increased expression of functionally active estrogen receptor after steroid-deprivation of MCF-7Ca human breast cancer cells in vitro.
- Published
- 2002
30. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors
- Author
-
Dean B. Evans, Ajay S. Bhatnagar, William R. Miller, Angela Brodie, and Brian J. Long
- Subjects
medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Cell ,Adipose tissue ,Anastrozole ,Pharmacology ,Biochemistry ,Endocrinology ,Aromatase ,Cricetinae ,Nitriles ,medicine ,Tumor Cells, Cultured ,Animals ,Humans ,Enzyme Inhibitors ,Molecular Biology ,biology ,Fadrozole ,Aromatase Inhibitors ,Letrozole ,Cell Biology ,Triazoles ,medicine.anatomical_structure ,Estrogen ,biology.protein ,Molecular Medicine ,Intracellular ,medicine.drug - Abstract
An important feature of the pharmacological profile of aromatase inhibitors is the ability of the various inhibitors to inhibit intracellular aromatase. It is now well documented that a large proportion of breast tumors express their own aromatase. This intratumoral aromatase produces estrogen in situ and therefore may contribute significantly to the amount of estrogen to which the cell is exposed. Thus it is not only important that aromatase inhibitors potently inhibit the peripheral production of estrogen and eliminate the external supply of estrogen to the tumor cell, but that they in addition potently inhibit intratumoral aromatase and prevent the tumor cell from making its own estrogen within the cell. To study the inhibition of intracellular aromatase we have compared the aromatase-inhibiting potency of the non-steroidal aromatase inhibitors, letrozole, anastrozole and fadrozole in a variety of model cellular endocrine and tumor systems which contain aromatase. We have used hamsters ovarian tissue fragments, adipose tissue fibroblasts from normal human breast, the MCF-7Ca human breast cancer cell line transfected with the human aromatase gene and the JEG-3 human choriocarcinoma cell line. Although letrozole and anastrozole are approximately equipotent in a cell-free aromatase system (human placental microsomes), letrozole is consistently 10-30 times more potent than anastrozole in inhibiting intracellular aromatase in intact rodent cells, normal human adipose fibroblasts and human cancer cell lines. Whether these differences between letrozole and anastrozole are seen in the clinical setting will have to await the results of clinical trials which are currently in progress.
- Published
- 2001
31. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer
- Author
-
Yang Liu, Angela Brodie, Dmitry N. Grigoryev, Mark Gimbel, Qing Lu, and Brian J. Long
- Subjects
Cancer Research ,medicine.medical_specialty ,Time Factors ,medicine.drug_class ,Anastrozole ,Mice, Nude ,Mice ,Aromatase ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Nitriles ,Tumor Cells, Cultured ,Medicine ,Animals ,Humans ,Enzyme Inhibitors ,skin and connective tissue diseases ,Fulvestrant ,Analysis of Variance ,Mice, Inbred BALB C ,Aromatase inhibitor ,biology ,Estradiol ,business.industry ,Aromatase Inhibitors ,Letrozole ,Estrogen Antagonists ,Mammary Neoplasms, Experimental ,Triazoles ,Antiestrogen ,Disease Models, Animal ,Tamoxifen ,Endocrinology ,Oncology ,Estrogen ,biology.protein ,Cancer research ,Female ,Drug Screening Assays, Antitumor ,business ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
We have previously established a model for postmenopausal, hormone‐dependent breast cancer in nude mice which is responsive to both antiestrogens and aromatase inhibitors. In this model, MCF‐7 human breast carcinoma cells transfected with the aromatase gene (MCF‐7CA) synthesize sufficient estrogen to form tumors in ovariectomized nude mice. In the present study we used this intratumoral aromatase model to investigate the effects on tumor growth of the new nonsteroidal aromatase inhibitors letrozole (CGS 20,267) and anastrozole (ZD 1033) and the antiestrogens tamoxifen (ICI 47,474) and faslodex (ICI 182,780). Furthermore, we determined whether the inhibition of estrogen synthesis together with inhibition of estrogen action would be more effective in controlling breast tumor growth. The results of our studies indicate that the aromatase inhibitors anastrozole and letrozole, as well as the new pure antiestrogen faslodex, have potent antitumor effects in the mouse model. In the treatment of mice with mammary tumors, letrozole was more effective in suppressing tumor growth than anastrozole. This was consistent with the Ki values of these inhibitors against placental aromatase and the IC50 values in cell culture (MCF‐7CA), which indicated the greater potency of letrozole as an aromatase inhibitor. Letrozole also had greater antitumor effects than tamoxifen and faslodex. The antitumor effect of letrozole was substantial, making it difficult to detect any additional effect on the tumors when letrozole was combined with the antiestrogens. However, the combined treatment of anastrozole + tamoxifen and anastrozole + faslodex also did not increase efficacy compared to the aromatase inhibitor alone. In addition, combining the two antiestrogens did not suppress tumor growth more effectively than faslodex alone. Our results show that treatment with the combinations of aromatase inhibitors with either tamoxifen or faslodex are not more effective in blocking estrogen stimulation of tumor growth than the aromatase inhibitors alone.
- Published
- 1999
32. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds
- Author
-
Brian J. Long, Qing Lu, Yang Liu, Xin Wang, Angela Brodie, Katsuya Kato, Yang-zhi Ling, and Ivo P. Nnane
- Subjects
Male ,endocrine system ,medicine.medical_specialty ,Cholestenone 5 alpha-Reductase ,Pharmacology ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Endocrinology ,Prostate ,Internal medicine ,Microsomes ,Testis ,medicine ,Animals ,Humans ,Enzyme Inhibitors ,IC50 ,Testosterone ,Androgen biosynthetic process ,Steroid 17-alpha-Hydroxylase ,Rats ,medicine.anatomical_structure ,chemistry ,Dihydrotestosterone ,Finasteride ,Microsome ,Androgens ,Ketoconazole ,Steroids ,Oxidoreductases ,medicine.drug - Abstract
The C17,20-lyase and 5α-reductase are key enzymes in the biosynthesis of androgens. The effects of novel steroidal compounds were evaluated as inhibitors against both human C17,20-lyase and 5α-reductase in vitro. The concentrations of testosterone (T) and dihydrotestosterone (DHT) in the prostate, testis and serum and changes in the tissue weights were also determined in rats treated with the novel inhibitors. L-12 and L-26 showed potent inhibition of human testicular C17,20-lyase with IC50 values of 50 and 25 nm, respectively. L-12, L-38, and I-47 showed moderate inhibition of human testicular C17,20-lyase with IC50 values of 75, 108, and 70 nm, respectively similar to ketoconazole (78 nm). Interestingly, L-6, L-26, and L-38 also showed some inhibitory activity against 5α-reductase with IC50 values of 75, 125, and 377 nm, respectively. Finasteride, an inhibitor of 5α-reductase had an IC50 value of 33 nm. However, ketoconazole did not inhibit 5α-reductase nor did finasteride inhibit C17,20-lyase. Treatment of normal male rats with several of these novel inhibitors (50 mg/kg·day, sc, for 14 consecutive days) caused about 45–91% decrease in serum, testicular and prostatic T concentration. Similarly, serum and prostatic DHT concentration were significantly decreased in rats treated with these novel compounds by 50–90% compared with controls. Surgical castration caused almost complete elimination of circulating T and DHT concentration in rat tissues. L-6 and L-12 were the most effective and reduced the wet weight of the prostate by 50%. Although future improvements in their bioavailability are necessary, these novel steroidal compounds show promise as potential agents for reducing T and DHT levels in patients with androgen dependent diseases.
- Published
- 1999
33. The effects of aromatase inhibitors and antiestrogens in the nude mouse model
- Author
-
Jiping Wang, Brian J. Long, Angela Brodie, Qing Lu, Yang Liu, and Wei Yue
- Subjects
Cancer Research ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,medicine.drug_class ,Anastrozole ,Mice, Nude ,Mice ,Nude mouse ,Internal medicine ,Nitriles ,medicine ,Tumor Cells, Cultured ,Animals ,Humans ,Aromatase ,Enzyme Inhibitors ,skin and connective tissue diseases ,Fulvestrant ,biology ,Estradiol ,Aromatase Inhibitors ,Letrozole ,Estrogen Antagonists ,Mammary Neoplasms, Experimental ,Triazoles ,Antiestrogen ,biology.organism_classification ,Tamoxifen ,Endocrinology ,Oncology ,Estrogen ,Cancer cell ,biology.protein ,Female ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
The effects of antiestrogens, tamoxifen and ICI 182,780, and aromatase inhibitors, arimidex (anastrozole ZD1033) and letrozole (CGS 20,267), on the growth of tumors were studied in nude mice. In this model, estrogen dependent MCF-7 human breast cancer cells stably transfected with the aromatase gene were inoculated in four sites per mouse. Sufficient estrogen is produced from aromatization of androstenedione supplement (0.1 mg/mouse/day) by the cells to stimulate their proliferation, tumor formation, and maintain the uterus similar to that of the intact mouse. Once the tumors reached a measurable size, the mice were injected with antiestrogen or inhibitor for 35–56 days. Tumor volumes were measured weekly. At autopsy, the tumors were removed, cleaned, and weighed. Statistical data was determined from tumor weights. Both antiestrogens were effective in reducing tumor growth in these mice. Tamoxifen appears to be more effective than ICI 182,780, although the former stimulated the uterine weight whereas the pure antiestrogen did not. However, both aromatase inhibitors were more effective than the antiestrogens. Tumor regression was observed with letrozole. Thus, after-treatment tumor weights were less than those of a group of mice at the start of treatment. The aromatase inhibitors also reduced the weight of the uterus, suggesting that these compounds, as well as the pure antiestrogen, may not cause endometrial proliferation, unlike tamoxifen. These aromatase inhibitors may not only benefit patients who have relapsed from tamoxifen, but may be more effective in patients as first line agents for suppressing the effects of estrogen.
- Published
- 1998
34. Reduced levels of cathepsin D associated with tamoxifen resistance and estrogen independence in the ZR-75-1 human breast cancer cell line
- Author
-
Brian J. Long and Hendrik W. Van Den Berg
- Subjects
Cancer Research ,Cathepsin D ,Gene Expression ,Breast Neoplasms ,Biology ,Cell Line ,Pregnenediones ,Gene expression ,Tumor Cells, Cultured ,Humans ,Secretion ,Estradiol ,Progesterone Congeners ,Molecular biology ,In vitro ,Clone Cells ,Blot ,ErbB Receptors ,Molecular Weight ,Tamoxifen ,Secretory protein ,Oncology ,Receptors, Estrogen ,Cell culture ,Drug Resistance, Neoplasm ,Cancer cell ,Female ,Receptors, Progesterone - Abstract
The expression and secretion of cathepsin D by ZR-75-1 human breast cancer cells, and tamoxifen-resistant (ZR-75-9a1) and estrogen-independent (ZR-PR-LT) variants was examined by electrophoresis of labeled proteins and Western blotting. Secreted proteins of 160 kDa, 52 kDa and 34 kDa were identified, and in ZR-75-1 cells, they were shown to be estrogen-inducible. Treatment of ZR-75-9a1 cells with 17β-estradiol (E2) and the progestin ORG 2058 increased secretion of the 52 kDa protein; ZR-PR-LT cells were unaffected. Western blotting showed that each cell line expressed high levels of the 52 kDa and 34 kDa forms of cathepsin D but that relatively little was being secreted. Each cell line secreted 52 kDa procathepsin D, but 34 kDa mature-cathepsin D was not detected as a secreted protein. ZR-75-1 cells expressed and secreted the highest levels of cathepsin D while ZR-75-9al cells expressed and secreted the least.
- Published
- 1996
35. Gene expression changes during acquired resistance to tamoxifen; a preclinical model of post-menopausal breast cancer
- Author
-
Brian J. Long, S. Moore, A. Brodie, Nicol Macpherson, Danijela Jelovac, T. Olivotto, C. C. Nelson, and A. Thiantanawat
- Subjects
Cancer Research ,medicine.medical_specialty ,Aromatase inhibitor ,biology ,business.industry ,medicine.drug_class ,Letrozole ,medicine.disease ,Breast cancer ,Endocrinology ,Oncology ,Estrogen ,Internal medicine ,Cancer cell ,medicine ,Cancer research ,biology.protein ,Androstenedione ,Aromatase ,skin and connective tissue diseases ,business ,Tamoxifen ,medicine.drug - Abstract
3147 Background: Most metastatic breast cancers initially respond to hormonal treatment but all become resistant to these treatments over time. The genetic events that occur during acquired resistance are unknown. To examine the gene expression changes during acquired hormonal resistance, we used a model that mimics ER positive breast cancers in the post-menopausal setting with the tumors responsive to both Tamoxifen (TAM) and aromatase inhibitors. Tumors were analyzed with high density cDNA microarrays to identify genes associated with TAM resistance. Methods: Aromatase-transfected MCF-7Ca human breast cancer cells were grown as tumor xenografts in female ovariectomized athymic nude mice in which an androstenedione supplement was converted to estrogen to stimulate tumor growth. When tumor volume was approximately 300 mm3, the animals were grouped (4 groups, each with n=20) for continued supplementation with androstenedione (Δ4A) only (control), Letrozole (an aromatase inhibitor) 10 μg/day + Δ4A, TAM 100 ...
- Published
- 2004
36. Identification of human plasma proteins using the Laemmli method of gel electrophoresis
- Author
-
G. Brian Wisdom, George J. Allen, and Brian J. Long
- Subjects
Electrophoresis ,Gel electrophoresis ,Chromatography ,Chemistry ,Immunoblotting ,Blood Proteins ,Gel electrophoresis of proteins ,Biochemistry ,Molecular Weight ,Reference Values ,Human plasma ,Pulsed-field gel electrophoresis ,Humans ,Identification (biology) - Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.